Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: Results from two patients treated on a clinical study

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 6, 2011, Pages 492-500

  Mohammed, Tabraiz A ^a   Dennie, Trevor ^a   Holen, Kyle D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; LAPATINIB; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL STUDY; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LIVER BIOPSY; LIVER DISEASE; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; PERIPHERAL NEUROPATHY; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES;

EID: 79959918158     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Atlanta: American Cancer Society; 2011.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
3. Bohm B, Schwenk W, Hucke H P, et al. Does methodic long-term follow-up afect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993;36:280-286.
4. Kjeldsen BJ, Kronborg O, Fenger C, et al. The pattern of recurrent colorectal cancer in a prospective randomized study and the characteristics of diagnostic tests. Int J Colorectal Dis. 1997;12:329-334.
5. Penna C, Nordlinger B. Colorectal metastases (liver and lung). Surg Clin North Am. 2002;82:1075-1090.
6. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fuorouracil: evidence of signifcant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407-1418.
7. Modulation of fuorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992;10:896-903.
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fuorouracil with or without oxaliplatin as frst-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
9. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fuorouracil-leucovorin as frst-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
10. Saltz LB, Cox J V, Blanke C, et al. Irinotecan plus fuorouracil and leu-covorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
11. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fuorouracil compared with fuorouracil alone as frst-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041-1047.
12. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxalipla-tin): Active frstline therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-2091.
13. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fuorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-2012.
14. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol. 2007;25:4000.
15. Bengala C, Bettelli S, Bertolini F, et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Onc. 2009;20:469-474.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinote-can, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
17. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as frst-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
18. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
19. Sobrero A F, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fuoropyrimidine and oxaliplatin failure in patients with meta-static colorectal cancer. J Clin Oncol. 2008;26:2311-2319.
20. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
21. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991;47:87.
22. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112:1103-1113.
23. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8:47-61.
24. Learn PA, Krishnegowda N, Talamantez J, Kahlenberg MS. Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. J Surg Res. 2006;136:227-231.
25. Cerea G, Ricotta R, Schiavetto I, et al. Cetuximab for treatment of metastatic colorectal cancer. Ann Oncol. 2006;17:766-7.
26. Zhou Y, Li S, Hu Y P, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006;66:404-411.
27. Kim H P, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyro-sine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009;4:e5933.